Radiotherapy as Salvage Treatment in Intraocular Lymphoma: A Case Report.

Intraocular lymphoma Primary central nervous system lymphoma Radiotherapy

Journal

Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601

Informations de publication

Date de publication:
Historique:
received: 06 10 2020
accepted: 12 10 2020
entrez: 29 3 2021
pubmed: 30 3 2021
medline: 30 3 2021
Statut: epublish

Résumé

A 67-year-old previously healthy woman presented with progressive visual impairment including bitemporal hemianopsia. A brain magnetic resonance imaging revealed a contrast-enhancing mass in the optic chiasm, spreading along the left optic tract. The patient underwent a transcranial biopsy of the left optical tract that yielded a diagnosis of diffuse large B-cell lymphoma. CT scans of the chest, abdomen, and pelvis, PET-CT, and bone marrow biopsy revealed no evidence of systemic lymphoma. Thus, the final diagnosis was of primary central nervous system lymphoma of the optic chiasm. Systemic treatment was initiated with full response. Six months after the end of the treatment, recurrence at cerebellum parenchyma and left tentorium was recorded. A new systemic treatment achieved full response. A second recurrence was noted in an optical coherence tomography of the right eye, 2 years after the initial diagnosis. The patient was treated with intravitreal methotrexate with initial success, but eventual failure after 10 months. Intravitreal rituximab was used with no effect. The patient was then referred to radiotherapy and underwent external beam radiotherapy with VMAT. There were no acute toxicities to report. After the radiotherapy treatment, at 1-year follow-up, the patient has no evidence of disease. Long-term toxicities were recorded and are considered manageable. The present case emphasizes the role of ocular irradiation as an option in the management of intraocular lymphoma patients, including in the salvage setting, with an acceptable ocular toxicity profile.

Identifiants

pubmed: 33776701
doi: 10.1159/000512216
pii: cro-0014-0184
pmc: PMC7983581
doi:

Types de publication

Case Reports

Langues

eng

Pagination

184-189

Informations de copyright

Copyright © 2021 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to declare.

Références

Cancer Sci. 2016 Oct;107(10):1458-1464
pubmed: 27412324
Lancet. 2003 Jan 25;361(9354):323-31
pubmed: 12559880
Hematol Oncol Clin North Am. 2005 Aug;19(4):739-49, viii
pubmed: 16083834
Ophthalmology. 1987 Dec;94(12):1631-9
pubmed: 3323986
Jpn J Ophthalmol. 2006 Sep-Oct;50(5):474-478
pubmed: 17013703
Leuk Lymphoma. 2006 Sep;47(9):1800-5
pubmed: 17064991
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S28-35
pubmed: 20171514
Surv Ophthalmol. 2014 Sep-Oct;59(5):503-16
pubmed: 24560125
Neurology. 2008 Oct 21;71(17):1355-60
pubmed: 18936428
Graefes Arch Clin Exp Ophthalmol. 2004 Nov;242(11):901-13
pubmed: 15565454
Arch Ophthalmol. 1997 Sep;115(9):1152-6
pubmed: 9298056
J Natl Cancer Inst. 1996 May 15;88(10):675-9
pubmed: 8627644
Int J Ophthalmol. 2017 Aug 18;10(8):1301-1307
pubmed: 28861359

Auteurs

Raul Colaço (R)

Radiotherapy Department, Instituto Português de Oncologia Francisco Gentil E.P.E, Lisbon, Portugal.

Mariana Portela (M)

Ophthalmology Department, Hospital de Egas Moniz Centro Hospitalar Lisboa Ocidental E.P.E, Lisbon, Portugal.

Ilda Costa (I)

Neurology Department, Instituto Português de Oncologia Francisco Gentil E.P.E, Lisbon, Portugal.

Marta Guedes (M)

Ophthalmology Department, Hospital de Egas Moniz Centro Hospitalar Lisboa Ocidental E.P.E, Lisbon, Portugal.

António Mota (A)

Radiotherapy Department, Instituto Português de Oncologia Francisco Gentil E.P.E, Lisbon, Portugal.

Classifications MeSH